================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB/A
(Mark One)
|X| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2004
OR
|_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934 For the transition period from to
Commission File Number: 1-11765
MEDJET INC.
(Name of Small Business Issuer as Specified in its Charter)
DELAWARE 22-3283541
(State or Other Jurisdiction of (I.R.S. Employer Identification No.)
Incorporation or Organization)
1535 COLES AVENUE
MOUNTAINSIDE, NJ 07092
(Address of Principal Executive Offices)
908 233 4677
(Issuer's Telephone Number, Including Area Code)
Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. YES |X| NO
|_|
As of August 20, 2004, 3,901,431 shares of Common Stock, par value
$.001 per share, were outstanding.
Transitional Small Business Disclosure Format: Yes |_| No |X|
================================================================================
EXPLANATORY NOTE
This Form 10-QSB/A amends Part II, Item 1 of the Form 10-QSB of Medjet Inc.
filed with the Securities and Exchange Commission on August 20, 2004.
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
On August 18, 2004, the United States District Court for the District of New
Jersey ("U.S. District Court") granted our Motion for Summary Judgment,
dismissing the New Jersey Institute of Technology ("NJIT")'s claim of failing to
name a NJIT professor and/or NJIT research associate as a co-inventor to our
U.S. Patent No. 5,556,406 on "Corneal Template and Surgical Procedure for
Refractive Correction" (the "NJIT litigation"). Certain of NJIT's claims
relating to damage to NJIT were remanded to the Superior Court of the State of
New Jersey, where such claims are being dealt with as counterclaims to our suit
in which NJIT is the defendant. However, in view of a previously existing
summary judgment in that court against NJIT, we are optimistic that these claims
will be dismissed.
The NJIT litigation is described in our Quarterly Report for the fiscal quarter
ended March 31, 2004.
Other than as described above and on our Quarterly Report on Form 10-QSB for the
quarter ended March 31, 2004, there have been no material developments in any of
the reported legal proceedings.
INDEX TO EXHIBITS
31.1 Certification of Chief Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
31.2 Certification of Principal Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
32 Certification of Chief Executive Officer and Principal Financial Officer
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dated: August 24, 2004 MEDJET INC.
/s/ Eugine I. Gordon
-------------------
Eugene I. Gordon, Ph.D.
Chairman of the Board,
Chief Executive Officer,
Secretary and Treasurer
(Principal Financial Officer)
5